Differential effects of homocysteine on porcine endothelial and vascular smooth muscle cells. 2002

Hae-Young Lee, and In-Ho Chae, and Hyo-Soo Kim, and Young-Bae Park, and Yun-Shik Choi, and Young-Woo Lee, and Sun-Jung Park, and Young-Joo Cha
Department of Internal Medicine, Seoul National University College of Medicine, Chongno-Gu, Korea.

High concentrations of homocysteine damage endothelial cells and lower concentrations increase vascular smooth muscle cell (VSMC) growth. This study investigated the effects of various concentrations of homocysteine on endothelial cells (VECs) and VSMCs in terms of cell survival, proliferation, and function. VECs and VSMCs from porcine thoracic aorta were studied. These cells were exposed to homocysteine in concentrations of 20 microM, 400 microM, and 1 mM every 8 h for 24 h, and its effect on cell survival, proliferation, and function were studied using methylthiazoletetrazolium assay, [3H]-thymidine incorporation test, and 6-keto-prostaglandin F1alpha enzyme-linked immunosorbent assay for VECs, and platelet-derived growth factor (PDGF) enzyme-linked immunosorbent assay for VSMCs, respectively. In VECs, 20 microM of homocysteine reduced the viable cell count to 95 +/- 31%, 400 microM reduced it to 89 +/- 35%, 1,000 microM reduced it to *58 +/- 29% (control = 100 +/- 30%, n = 18, *p < 0.05). In VSMCs, 20 microM of homocysteine slightly increased the viable cell count to 106 +/- 30%, but there was no statistical significance; 400 microM of homocysteine reduced the viable cell count to *74 +/- 29%, 1,000 microM to *50 +/- 24% (control = 100 +/- 28%, n = 18, *p < 0.05). In VECs, 20 microM of homocysteine reduced [3H]-thymidine uptake by 98 +/- 14%, 400 microM reduced it by *82 +/- 17%, 1,000 microM reduced it by *66 +/- 17% (control = 100 +/- 12, n = 6, *p < 0.05), respectively. But in VSMCs, 20 microM of homocysteine significantly increased [3H]-thymidine uptake (*131 +/- 16%), and thereafter, homocysteine decreased VSMCs [3H]-thymidine uptake, 400 microM by *24 +/- 7%, 1,000 microM by *29 +/- 10% (control = 100 +/- 16, n = 6, *p < 0.05), respectively. Homocysteine decreased VEC prostacyclin secretion in a dose-dependent manner, 20 microM by 105 +/- 0.65 pg/100 microl, 400 microM by *100 +/- 2.37 pg/100 microl, 1,000 microM by *93 +/- 2.54 pg/100 microl (control = 107 +/- 1.26 pg/100 microl, n = 6, *p = 0.007). In VSMCs, 20 microM of homocysteine slightly increased PDGF secretion by 62.2 +/- 20.7 pg/100 microl, but there was little statistical significance (p = 0.13); 400 microM of homocysteine reduced PDGF secretion by *28.9 +/- 10.7 pg/100 microl, and 1,000 microM reduced it by *21.3 +/- 4.7 pg/100 microl (control = 54.5 +/- 9.3 pg/100 microl, n = 6, *p < 0.05). High concentrations of homocysteine damaged both VECs and VSMCs with respect to cell survival, proliferation, and function. By increasing exposure to homocysteine, it was shown that physiologic high concentrations of homocysteine enhanced VSMC proliferation.

UI MeSH Term Description Entries
D009131 Muscle, Smooth, Vascular The nonstriated involuntary muscle tissue of blood vessels. Vascular Smooth Muscle,Muscle, Vascular Smooth,Muscles, Vascular Smooth,Smooth Muscle, Vascular,Smooth Muscles, Vascular,Vascular Smooth Muscles
D010982 Platelet-Derived Growth Factor Mitogenic peptide growth hormone carried in the alpha-granules of platelets. It is released when platelets adhere to traumatized tissues. Connective tissue cells near the traumatized region respond by initiating the process of replication. Platelet Derived Growth Factor,Factor, Platelet-Derived Growth,Growth Factor, Platelet-Derived
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004730 Endothelium, Vascular Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components. Capillary Endothelium,Vascular Endothelium,Capillary Endotheliums,Endothelium, Capillary,Endotheliums, Capillary,Endotheliums, Vascular,Vascular Endotheliums
D006710 Homocysteine A thiol-containing amino acid formed by a demethylation of METHIONINE. 2-amino-4-mercaptobutyric acid,Homocysteine, L-Isomer,2 amino 4 mercaptobutyric acid,Homocysteine, L Isomer,L-Isomer Homocysteine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001011 Aorta The main trunk of the systemic arteries. Aortas

Related Publications

Hae-Young Lee, and In-Ho Chae, and Hyo-Soo Kim, and Young-Bae Park, and Yun-Shik Choi, and Young-Woo Lee, and Sun-Jung Park, and Young-Joo Cha
September 2007, Arteriosclerosis, thrombosis, and vascular biology,
Hae-Young Lee, and In-Ho Chae, and Hyo-Soo Kim, and Young-Bae Park, and Yun-Shik Choi, and Young-Woo Lee, and Sun-Jung Park, and Young-Joo Cha
May 2012, Journal of biomedical materials research. Part A,
Hae-Young Lee, and In-Ho Chae, and Hyo-Soo Kim, and Young-Bae Park, and Yun-Shik Choi, and Young-Woo Lee, and Sun-Jung Park, and Young-Joo Cha
August 1981, Biochemical pharmacology,
Hae-Young Lee, and In-Ho Chae, and Hyo-Soo Kim, and Young-Bae Park, and Yun-Shik Choi, and Young-Woo Lee, and Sun-Jung Park, and Young-Joo Cha
November 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research,
Hae-Young Lee, and In-Ho Chae, and Hyo-Soo Kim, and Young-Bae Park, and Yun-Shik Choi, and Young-Woo Lee, and Sun-Jung Park, and Young-Joo Cha
October 2002, Photodermatology, photoimmunology & photomedicine,
Hae-Young Lee, and In-Ho Chae, and Hyo-Soo Kim, and Young-Bae Park, and Yun-Shik Choi, and Young-Woo Lee, and Sun-Jung Park, and Young-Joo Cha
September 2015, American journal of physiology. Cell physiology,
Hae-Young Lee, and In-Ho Chae, and Hyo-Soo Kim, and Young-Bae Park, and Yun-Shik Choi, and Young-Woo Lee, and Sun-Jung Park, and Young-Joo Cha
May 1989, Biochemical and biophysical research communications,
Hae-Young Lee, and In-Ho Chae, and Hyo-Soo Kim, and Young-Bae Park, and Yun-Shik Choi, and Young-Woo Lee, and Sun-Jung Park, and Young-Joo Cha
January 2015, BioResearch open access,
Hae-Young Lee, and In-Ho Chae, and Hyo-Soo Kim, and Young-Bae Park, and Yun-Shik Choi, and Young-Woo Lee, and Sun-Jung Park, and Young-Joo Cha
January 2014, Indian journal of pharmacology,
Hae-Young Lee, and In-Ho Chae, and Hyo-Soo Kim, and Young-Bae Park, and Yun-Shik Choi, and Young-Woo Lee, and Sun-Jung Park, and Young-Joo Cha
January 2012, American journal of physiology. Heart and circulatory physiology,
Copied contents to your clipboard!